450 Studies Now Enrolling
A Phase 1 Basket Study Evaluating the Safety and Feasibility of T Plex, Autologous Customized T Cell Receptor Engineered T Cells Targeting Multiple Peptide/HLAAntigens in Participants with Antigen positive Locally Advanced (Unresectable) or Metastatic Solid Tumors
Study of T Plex in Patients with Advanced or Metastatic Solid Tumors
| Sponsor: | TScan Therapeutics, Inc |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAU7036 |
| U.S. Govt. ID: | NCT05973487 |
| Contact: | Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
Additional Study Information:
The purpose of the study is to learn if the study treatments TSC-204-A0201, TSC 200-A020, and TSC-204-C0702 alone or in combination, referred to as T-Plex, are safe and effective in treating your type of cancer. T-Plex has not yet been approved by the Food and Drug Administration (FDA). This is a first-in-human study, which means that these products have never been administered to humans before. You are unlikely to benefit from taking part in this study. Cancers include: Colon and Rectal Cancer, Lung Cancer, Cervical Cancer, Ovarian Cancer, Head and Neck/Oral Cancers, Melanoma, and Testicular Cancer.
